The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
